DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer [Yahoo! Finance]
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer
Asian Market Stocks That May Be Trading Below Estimated Value In December 2025 [Yahoo! Finance]
3 Asian Stocks That Investors Might Be Undervaluing By Up To 35.8% [Yahoo! Finance]